According to Yunnan Baiyao, on October 29, 2026, the flurbiprofen gel patch developed by the Wuxi Center of the Central Research Institute of Yunnan Baiyao Group and declared by Yunnan Baiyao Group Wuxi Pharmaceutical Co., Ltd. was accepted by the China Drug Administration for drug registration and marketing. As a non-steroidal anti-inflammatory drug, flubiprofen gel patch is clinically used for anti-inflammatory analgesia such as osteoarthritis, periodontal inflammation, muscle pain, and traumatic swelling and pain.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.